Poviztra 1mg FlexTouch is used to:

• Manage obesity: It is used with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity.

• Manage overweight with weight-related health conditions: It may be prescribed for adults with overweight who have at least one weight-related condition.

• Support cardiovascular risk reduction: Semaglutide is indicated to reduce the risk of major adverse cardiovascular events in eligible adults with established cardiovascular disease and obesity or overweight.

Poviztra 1mg FlexTouch contains Semaglutide, which activates GLP-1 receptors involved in appetite regulation and food intake.

It helps increase fullness, reduce hunger and lower food intake. It also slows stomach emptying, which can contribute to appetite control and weight management when combined with diet and physical activity.

Tell your doctor about all prescription medicines, over-the-counter medicines, vitamins and herbal supplements you take.

• Insulin or sulfonylureas: These medicines can increase the risk of low blood sugar when used with Semaglutide.

• Other GLP-1 medicines or Semaglutide products: Do not use Poviztra with another Semaglutide-containing medicine or GLP-1 receptor agonist unless specifically prescribed.

• Oral medicines: Semaglutide may delay stomach emptying and can affect the absorption of some oral medicines.

• Store Poviztra 1mg FlexTouch in a refrigerator at 2°C to 8°C.

• Do not freeze it or use it if frozen.

• Protect the pen from light.

• Keep it out of the sight and reach of children.

• Follow the packaging instructions for storage after first use.

Poviztra 1mg FlexTouch is administered once a week by injection under the skin of the abdomen, thigh or upper arm.

The 1mg strength forms part of the gradual dose-escalation schedule. Your doctor will decide when to increase the dose based on your response and how well you tolerate treatment.

Use the FlexTouch pen only after you have been shown how to inject it correctly. Use a new needle for each injection and do not share the pen.

If you miss a dose, follow the missed-dose instructions supplied with your product and prescription. Do not take two doses together.

Common side effects:

• Nausea

• Vomiting

• Diarrhoea

• Constipation

• Abdominal pain

• Headache

• Dizziness

• Indigestion

• Decreased appetite

These effects are more likely when the dose is increased and may become less noticeable as the body adjusts.

Serious side effects:

• Severe or persistent abdominal pain, which may indicate pancreatitis

• Severe allergic reactions such as swelling of the face, lips, tongue or throat

• Persistent vomiting or diarrhoea that may lead to dehydration

• Gallstones or inflammation of the gallbladder

• Sudden or worsening changes in vision

• Low blood sugar, particularly when used with insulin or sulfonylureas

Seek medical attention if you develop severe or persistent symptoms.

• Use Poviztra exactly as prescribed and do not change the weekly dose yourself.

• Follow your recommended reduced-calorie diet and physical activity plan.

• Drink enough fluids, particularly if you have vomiting or diarrhoea.

• Rotate injection sites rather than repeatedly injecting into the same area.

• Use a new needle for every injection and never share your pen.

• Tell your doctor if you have diabetic retinopathy or develop changes in vision.

• Inform your doctor before surgery or a procedure involving general anaesthesia or deep sedation.

• Seek medical attention for severe or persistent abdominal pain.